| Programme |
| Wednesday 5 December |
| Chairman - Dr David Lathbury, AstraZeneca, UK |
| 13:40 |
|
Diastereoselective Reductive Amination of 2,2,2- Trifl uoroacetophenones and a-Aminoesters (pdf 280Kb)
Dr Greg Hughes, Merck-Frosst, Canada |
| 14:20 |
|
Process Aspects of Asymmetric Hydrogenation (pdf 680Kb)
Dr Ian Lennon, DowPharma, UK |
| 15:00 |
|
Lab Automation within Roche Synthesis & Process Research and Kilolaboratory
Dr Jean-Michel Adam, F. Hoffman-La Roche Ltd., Switzerland |
| 15:40 |
|
Tea
Process Chemistry Retrospectives |
| 16:10 |
|
SK&F92334 - Chemical Development of the Original Blockbuster
Dr Mike Forth, GlaxoSmithKline, UK |
| 16:40 |
|
Atenolol - 30 years of Life Cycle Management (pdf 2.2Mb)
Dr Stewart Jolly, AstraZeneca, UK |
| 17:10 |
|
'A Blast from the Past' - Removal of Azide Protection in the Identification and Development of a Manufacturing Process to Amlodipine (pdf 80Kb)
Mr Alan Pettman, Pfizer Global Research & Development, UK |
| |
|
|
| Thursday 6 December |
| Chairman- Dr Martin Jones, AstraZeneca, UK |
| 09:00 |
|
MK-524 - A Study in Modern Chemical Development (pdf 1.3Mb)
Dr Edward Grabowski, Merck Research Laboratories (retired), USA |
| 10:00 |
|
The Chemical Development of Tofi milast a PDE4 Inhibitor for Asthma and COPD (pdf 350 Kb)
Dr Lorraine Murtagh, Pfizer Global Research & Development, UK |
| 10:40 |
|
Coffee |
| 11:10 |
|
ZK-EPO, Chemical Development of a Totally Synthetic Epothilone Anti Cancer Drug
Dr Harribert Neh, Bayer Schering Pharma AG, Germany |
| 11:50 |
|
Green Manufacture of Chiral Alcohols using Custom Evolved Biocatalysts - Replacing Boron Based Reducing Agents
Dr Jim Lalonde, Codexis Inc, USA |
| 12:30 |
|
The Optimization and Scale-up Synthesis of BCL-2 Inhibitors
Dr David Hill, Abbott Laboratories, USA |
| |
|
|
| Chairman - Dr John Carey, GlaxoSmithKline, UK |
| 14:10 |
|
Large-Scale Application of Microreaction Technology within Commercial Chemical Production of DSM
Dr Peter Poechlauer, DSM Pharmaceutical Products, Austria |
| 14:50 |
|
The Synthesis of 9-Oxa-3,7-diazabicyclo[3.3.1]nonanes (Oxabispidines) and their use as Pharmaceutical Intermediates
Dr David Cladingboel, AstraZeneca, UK |
| 16:00 |
|
Increasing Process Understanding through Data Analysis (pdf 500Kb)
Dr Alan Brown, Syngenta, UK |
| 16:40 |
|
Process Research over 25 Years: A Personal Perspective (pdf 4.5Mb)
Professor Steven Ley, University of Cambridge, UK |
| |
|
|
| Friday 7 December |
| Chairman - Dr Graham McDougald, Syngenta, UK |
| 09:00 |
|
Process Development of Brivanib Alaninate, a VEGRF/FGFR Inhibitor
Dr Paul Lobben, Bristol-Myers Squibb, USA |
| 09:40 |
|
Directed Evolution of Enzymes: New Biocatalysts for Organic Synthesis
Professor Nick Turner, University of Manchester Winner of GlaxoSmithKline, AstraZeneca and Pfizer Prize for Process Chemistry Research 2007 |
| 11:10 |
|
Redesigning and Developing the Synthetic Route to 435466
Dr David Catterick, GlaxoSmithKline, UK |
| 11:50 |
|
Green Chemistry in the Pharmaceutical Industry
Dr Andy Wells, AstraZeneca, UK |